Skip to content
value.today

LB Pharmaceuticals Inc.

🇺🇸 New York, New York, USAPharmaceuticalsFounded 2015
Total raised
$117 M
2 rounds on record
Latest round
$111 M
Aug 2023
First round on record
Nov 2018
Today
Went public
See the company page

LB Pharmaceuticals Inc. is listed today as LB Pharmaceuticals Inc: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of LB Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$111 MNo. 2$50 to $250 million

LB Pharmaceuticals Inc.: Raise no. 2, Aug 2023

Investors in this round

6 investors had bought by the notice of Jan 10, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for LB Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$111 M of $111 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,465,000
Finders' fees
$735,000
Paid to its own people
$1,333,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Vaino · Executive Officer
  • Anna Eramo · Executive Officer
  • Marc Panoff · Executive Officer
  • Zachary Prensky · Executive Officer, Director
  • Chen Yu · Director
  • Rajul Jain · Director
  • Ran Nussbaum · Director
  • Rebecca Luse · Director
  • Robert Ruffolo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Agile Capital Markets · broker-dealer Agile Capital Markets · Paris, FranceSold in no state named, and outside the US
  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On the amounts: “The total offering amount of $110,730,354 consists of $75,000,000 new cash offering and $35,730,354 automatic conversion of existing convertible notes, for which notes (including underlying securities) a Form D was previously filed upon the original sale.”

Signed by Zachary Prensky, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 10, 2024. Read the notice at the SEC.

equity, optionsSEC
Nov 2018$6 MNo. 1$2 to $10 million

LB Pharmaceuticals Inc.: Raise no. 1, Nov 2018

Investors in this round

74 investors had bought by the notice of Dec 12, 2018: 74 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for LB Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $10 M offered; $4 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$670,163
Finders' fees
none
Paid to its own people
$550,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Vaino · Executive Officer
  • Marc Panoff · Executive Officer
  • Zachary Prensky · Executive Officer, Director
  • Edmund Sullivan · Director
  • Vincent Grattan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · broker-dealer Maxim Group LLC (CRD 120708) · New York, New YorkSold in AZ, CA, CO, CT, DC, FL, ID, IL, IN, KY, MA, MD, NJ, NV, NY, OH, PA, RI, SC, TX, WA, WI, and outside the US

Signed by Zachary Prensky, President. Source: SEC Form D, newest notice filed Dec 12, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • LB Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2024).

    SEC Form D · Jan 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2024

That is all the official record says: LB Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of LB Pharmaceuticals Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in LB Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Deep Track Biotechnology Master Fund, Ltd.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Deep Track Capital, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Pontifax Management 4 G.P. (2015) Ltd.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Vida Ventures GP III, L.L.C.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Vida Ventures III-A, L.P.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Vida Ventures III, L.P.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 74 investors.

Largest shareholders today

Institutions holding LB Pharmaceuticals Inc shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by LB Pharmaceuticals Inc.
NameRoleNamed in
Andrew VainoExecutive officerJan 2024
Anna EramoExecutive officerJan 2024
Marc PanoffExecutive officerJan 2024
Zachary PrenskyExecutive officerJan 2024
Chen YuDirectorJan 2024
Rajul JainDirectorJan 2024
Ran NussbaumDirectorJan 2024
Rebecca LuseDirectorJan 2024
Robert RuffoloDirectorJan 2024
Zachary PrenskyDirectorJan 2024
Simon BasseynDirectorSep 2023
Edmund SullivanDirectorDec 2018
Vincent GrattanDirectorDec 2018

Went public since 2025. Its SEC number is that of a company listed on a stock exchange.